STK11 and lung adenocarcinoma: An integrative study of genomics, transcriptomics, and proteomics in early-stage and chemo-refractory KRAS-mutant lung adenocarcinomas identified three major subsets defined by co-occurring genetic alterations in STK11/LKB1 (KL subgroup), TP53 (KP subgroup), and CDKN2A/B (KC subgroup) (29).